In this podcast episode, Meletios-Athanasios (Thanos) C. Dimopoulos, MD, and María-Victoria Mateos, MD, PhD, as they discuss the use of CELMoD agents to manage multiple myeloma, including: 

  • The recent FDA approval of iberdomide
  • Mechanism of action and differentiation from IMiDs
  • Current data and potential treatment settings

Presenters:
Meletios-Athanasios (Thanos) C. Dimopoulos, MD
Professor and Chairman
Plasma Cell Dyscrasias Unit
Section of Hematology and Medical Oncology
Department of Clinical Therapeutics
School of Medicine
National and Kapodistrian University of Athens
Alexandra Hospital
Athens, Greece

María-Victoria Mateos, MD, PhD
Myeloma Unit, Director
Professor of Medicine
University Hospital of Salamanca
Salamanca, Spain

Content based on an online CME program supported by an educational grant from Bristol Myers Squibb.

Link to full program:
https://bit.ly/4xgnHri

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Decera Clinical Education. Innehållet i podden är skapat av Decera Clinical Education och inte av, eller tillsammans med, Poddtoppen.